IMRX

Biotechnology IMRX RVMD Uncategorized VSTM

Immuneering plummets following phase 2 data of atebimetinib for pancreatic cancer

Jan 7, 2026

Biotechnology IMRX TEVA Uncategorized

Immuneering to be added to the Nasdaq Biotechnology Index

Dec 16, 2025